Intravenous human polyclonal anti-HBs IgG (brand: Hepatect CP) used as passive immunotherapy before liver resection or transplant; neutralizes HBV virions and HBsAg subviral particles to lower HBsAg, can be internalized by hepatocytes to inhibit HBsAg/virion secretion, and mediates Fc-dependent ADCC against HBV-infected hepatocytes; preclinical data suggest direct anti-tumor effects on HBV-related HCC tumor-initiating cells.
Human polyclonal anti-HBs IgG that passively neutralizes HBV virions and HBsAg subviral particles to lower circulating HBsAg; can be internalized by hepatocytes to inhibit HBsAg and virion secretion; Fc region engages Fc-gamma receptors to mediate ADCC against HBV-infected hepatocytes, with preclinical evidence of direct anti-tumor effects on HBV-related HCC tumor-initiating cells.
NO
INDIRECT
HBIG opsonizes HBsAg on infected hepatocytes; its Fc binds FCGR2A on immune effector cells to trigger ADCC/ADCP that kills the hepatocytes, not the FCGR2A-expressing cells.
Intravenous human polyclonal anti-HBs IgG (brand: Hepatect CP) used as passive immunotherapy before liver resection or transplant; neutralizes HBV virions and HBsAg subviral particles to lower HBsAg, can be internalized by hepatocytes to inhibit HBsAg/virion secretion, and mediates Fc-dependent ADCC against HBV-infected hepatocytes; preclinical data suggest direct anti-tumor effects on HBV-related HCC tumor-initiating cells.
Human polyclonal anti-HBs IgG that passively neutralizes HBV virions and HBsAg subviral particles to lower circulating HBsAg; can be internalized by hepatocytes to inhibit HBsAg and virion secretion; Fc region engages Fc-gamma receptors to mediate ADCC against HBV-infected hepatocytes, with preclinical evidence of direct anti-tumor effects on HBV-related HCC tumor-initiating cells.
NO
INDIRECT
HBIG binds HBsAg on infected hepatocytes; its Fc engages CD64 (FCGR1A) on myeloid effectors to trigger ADCC against the hepatocytes. CD64+ cells are effectors, not targets, and are not killed.
Recombinant humanized anti-EGFR (HER1/ErbB1) IgG monoclonal antibody that binds the extracellular domain of EGFR to block ligand binding and receptor activation, inhibiting downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling; may also mediate ADCC against EGFR-expressing tumor cells.
Humanized anti-EGFR IgG monoclonal antibody that binds the extracellular domain of EGFR (HER1), blocking ligand binding and receptor dimerization/activation to inhibit downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling and tumor cell proliferation; Fc-mediated effector function may also induce ADCC against EGFR-expressing cells.
YES
DIRECT
The anti-EGFR IgG binds EGFR on target cells and engages Fcγ receptors on immune effectors to trigger antibody-dependent cell-mediated cytotoxicity (ADCC; possibly CDC), leading to killing of EGFR-expressing cells.
Recombinant humanized anti-EGFR (HER1/ErbB1) IgG monoclonal antibody that binds the extracellular domain of EGFR to block ligand binding and receptor activation, inhibiting downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling; may also mediate ADCC against EGFR-expressing tumor cells.
Humanized anti-EGFR IgG monoclonal antibody that binds the extracellular domain of EGFR (HER1), blocking ligand binding and receptor dimerization/activation to inhibit downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling and tumor cell proliferation; Fc-mediated effector function may also induce ADCC against EGFR-expressing cells.
NO
INDIRECT
HLX07 binds EGFR on tumor cells and its Fc engages CD16a on NK cells to trigger ADCC, killing EGFR-positive targets; CD16a-expressing cells act as effectors and are not killed.
A bispecific antibody–drug conjugate (ADC) composed of fully human common light-chain antibodies that simultaneously target c-MET (HGF receptor) and EGFR on tumor cells. Dual binding promotes internalization and intracellular release of a cytotoxic payload, killing c-MET/EGFR–expressing cells and concurrently inhibiting MET and EGFR signaling. Administered intravenously as monotherapy every 3 weeks in Phase 1 dose escalation/expansion.
Bispecific antibody–drug conjugate that binds c-MET and EGFR on tumor cells, triggering internalization and lysosomal release of a cytotoxic payload to kill target-expressing cells, while concurrently inhibiting MET and EGFR signaling pathways.
YES
DIRECT
The bispecific ADC binds c-MET on tumor cells, is internalized, and releases a cytotoxic payload in lysosomes that kills the target-expressing cell (with concurrent MET/EGFR signaling inhibition).